The metabolic activation of the prohormone vitamin D 3 requires a 25-hydroxylation that has been reported to be catalyzed by both mitochondrial CYP27A and a microsomal vitamin D 3 25-hydroxylase in the liver. CYP27A has been extensively studied, but its role as a physiologically important vitamin D 3 25-hydroxylase has been questioned. The Northern blot and reverse transcription-polymerase chain reaction experiments revealed that CYP2D25 mRNA is expressed in higher levels in liver than in kidney, and in small amounts in adrenals, brain, heart, intestine, lung, muscle, spleen and thymus.
INTRODUCTION
Vitamin D 3 (cholecalciferol) is essential for the absorption of calcium and phosphate in the intestine and has effects on the regulation of growth and differentiation of certain specialized cell types. The prohormone vitamin D 3 is formed from 7-dehydrocholesterol in the skin under the influence of ultraviolet irradiation. Vitamin D 3 can also be derived from dietary sources. Vitamin D 2 (ergocalciferol), which differs structurally from vitamin D 3 in the side chain, has been frequently used to treat and prevent vitamin D deficiency and is used in parenteral vitamin formulations. A cytochrome P450-dependent 25- hydroxylation in the liver is the first step in the metabolic activation of both vitamin D 3 and vitamin D 2 into their active hormonal forms. It has been reported that extracts and enzyme preparations from other tissues e.g. kidney also contain this activity. The 25-hydroxylation is followed by the tightly regulated 1α-hydroxylation in the kidney, to form the biologically active compounds 1α,25-dihydroxyvitamin D 3 and 1α,25-dihydroxyvitamin D 2 , respectively (review, see 1).
A mitochondrial vitamin D 3 25-hydroxylase, CYP27A 1 , has been purified from several species and characterized (2) (3) (4) (5) (6) (7) . It is well established that this enzyme catalyzes the obligatory 27-hydroxylation of cholesterol and C 27 -sterols in bile acid biosynthesis. The tissue distribution of this mitochondrial enzyme is wide spread -its mRNA is found not only in liver but in most other tissues (3) . Leading authorities in the vitamin D field have expressed scepticism that a single enzyme, i.e. CYP27A, is responsible for the hepatic 25-hydroxylation as a whole (1) . There are several unexplained observations suggesting that a cytochrome P450 other than CYP27A performs 25-hydroxylation of vitamin D.
by guest on http://www.jbc.org/ Downloaded from 5 Thus, studies on patients having a mutated CYP27A gene, demonstrated a lack of 27-hydroxylation of C 27 -sterols in bile acid biosynthesis but not decreased serum levels of 25-hydroxyvitamin D 3 (8) . Mice with disrupted sterol 27-hydroxylase gene showed markedly reduced bile acid biosynthesis but the circulating 25-hydroxyvitamin D 3 levels were increased more than twofold (9) . Furthermore, the mitochondrial CYP27A does not RNA isolation −Tissues were obtained from six months old, castrated male pigs. Total RNA was extracted from liver, kidney, lung, heart, muscle, tymus, spleen, intensine, adrenal and brain using Rneasy Midi Reagent (Qiagen) following the manufacturers instructions.
Northern blot analysis −Total RNA, 30 µg, from each tissue was denatured for analysis of CYP2D25 and cyclophilin transcripts, separated on 1% denaturing agarose gels and subjected to Northern blot and hybridization with a 32 P-labeled 1624 bp Kpn I-Xba I fragment of pig liver microsomal CYP2D25 cDNA and a 400 bp fragment of rat cyclophilin cDNA as control (12) .
RT-PCR −Total RNA was extracted from different tissues of castrated male pigs as described above. First-strand cDNA synthesis was performed using 1 µg RNA from liver and kidney and 10 µg RNA from brain, lung, thymus, intestine, muscle, heart, adrenal and spleen and 30 pmol of a CYP2D25-specific antisense primer. The negative controls containing RNA without reverse transcriptase enzyme were included in each experiment. SDS/PAGE and immunoblottning −SDS/PAGE was carried out as described (10, 16) .
Electrophoresis and immunoblotting were performed with CYP2D25 and different human liver microsome samples from various donors, some of them with polymorphism for by more than 80% at a 50 µM concentration (Fig. 3) . This marked inhibition is to be expected since tolterodine was shown to be a substrate also for the microsomal vitamin D 3 25-hydroxylase (cf. above). Tolterodine had no effect on the 25-hydroxylation catalyzed by the mitochondrial vitamin D 3 25-hydroxylase CYP27A). Quinidine, an inhibitor of CYP2D6, inhibited the microsomal 25-hydroxylation at most by 50% in concentrations up to 125 µM (Fig. 3 ). Quinidine is a potent inhibitor of CYP2D6-catalyzed reactions in much lower concentrations -about 1 µM (17, 21) . In this concentration, the inhibition of the 25-hydroxylation was less than 20% (Fig. 3) . 
Northern blot and RT-PCR experiments on the tissue distribution of mRNA for pig microsomal CYP2D25 −RNA from various pig tissues was isolated and examined in
Northern blot experiments using the 32 P-labeled pig liver CYP2D25 cDNA as a probe (12) . With this method, mRNA for CYP2D25 was detected in liver and kidney but not in adrenals, brain, heart, intestine, lung, muscle, spleen or thymus (Fig. 4) . The presence of mRNA expressing CYP2D25 in kidney is supported by previous studies reporting the purification from pig kidney of a microsomal enzyme active in 25-hydroxylation of vitamin D 3 (29, 30) .
The results of the Northern blot experiments showed that CYP2D25 is expressed predominantly in liver and in lower amounts in kidney. However, a low expression in other tissues could not be excluded. Indeed, experiments with RT-PCR revealed that mRNA for CYP2D25 is present not only in liver and kidney, but also in small amounts in adrenals, brain, heart, intestine, lung, muscle, spleen and thymus (Fig. 5) . CYP2D6 is predominantly expressed in liver but has been reported to be expressed also in other tissues (31, 32) . The CYP2D enzymes in rats are expressed both in liver and extrahepatic tissues (24, 33) .
Comparison of the primary structures of CYP2D25 and CYP2D6 − Fig. 6 shows the deduced amino acid sequence of porcine CYP2D25 and alignment with the sequence of human CYP2D6. The overall amino acid identity between the two proteins was 77%.
The putative substrate recognition sites for CYP2 proteins (SRS-1 through SRS-6) described by Gotoh (34) were identified in CYP2D25 and compared with those in CYP2D6. These regions in CYP2D25 and CYP2D6 were not identical. The degree of identity between the substrate recognition sites of the two enzymes was as follows: 78% (Table 1) . analyzed for product formation by HPLC as described (17) . The product formed had the same retention time as the authentic 5-hydroxymethyl metabolite of tolterodine (17) . First-strand cDNA synthesis using total RNA from various tissues and PCR reactions with primers specific to CYP2D25 were performed as described in Experimental. The amplified PCR products (240 bp) were analyzed by electrophoresis on 2% agarose gels containing 0.5 µg/ml ethidium bromide. Comparison of the whole deduced sequences of pig CYP2D25 and human CYP2D6.
Experiments with recombinantly expressed human CYP2D6
Identical amino acid residues are indicated by shaded letters, while hyphens in the sequences indicate gaps introduced during the alignments. The sequences corresponding to the putative substrate recognition sites for CYP2 enzymes (SRS 1-6) described by Gotoh (34) are underlined. 
